Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nang Kuang Pharmaceutical CoTPE:1752 -1.10%88 PB Ratio is 1.27 as of Jul. 15, 2026, which is 28% below its 10-year median of 1.77. GuruFocus rates TPE:1752 with a GF Score™ of 88/100 and a GF Value™ of NT$46.62 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Nang Kuang Pharmaceutical Co ranks better than 70.3% on this metric.
Nang Kuang Pharmaceutical Co Ltd stock PB Ratio (=1.29) is close to 5-year low of 1.29.
The historical rank and industry rank for Nang Kuang Pharmaceutical Co's PB Ratio or its related term are showing as below:
TPE:1752'
s PB Ratio Range Over the Past 10 Years
Min: 1.28 Med: 1.77 Max: 3.25
Current: 1.28
During the past 13 years, Nang Kuang Pharmaceutical Co's highest PB Ratio was 3.25. The lowest was 1.28. And the median was 1.77.
TPE:1752's PB Ratio is ranked better than 70.3% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.05
vs TPE:1752: 1.28
During the past 12 months, Nang Kuang Pharmaceutical Co's average Book Value Per Share Growth Rate was 2.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 1.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 2.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 1.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Nang Kuang Pharmaceutical Co was 18.90% per year. The lowest was -0.70% per year. And the median was 2.90% per year.
Back to Basics: PB Ratio
Nang Kuang Pharmaceutical Co (TPE:1752) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Nang Kuang Pharmaceutical Co PB Ratio Related Terms
Nang Kuang Pharmaceutical Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Nang Kuang Pharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nang Kuang Pharmaceutical Co PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nang Kuang Pharmaceutical Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Nang Kuang Pharmaceutical Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Nang Kuang Pharmaceutical Co (TPE:1752) has a PB Ratio of 1.27 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Nang Kuang Pharmaceutical Co and its competitors. This is 28% below median its historical median of 1.77. Over the past decade, Nang Kuang Pharmaceutical Co's PB Ratio has ranged from 1.28 to 3.25. According to the industry distribution chart, Nang Kuang Pharmaceutical Co ranks #234 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 29.7%.
Is Nang Kuang Pharmaceutical Co's PB Ratio too high?
Nang Kuang Pharmaceutical Co's current PB Ratio of 1.27 is 28% below median its 10-year median of 1.77. Over the past 10 years, this metric has ranged from a low of 1.28 to a high of 3.25. The Medical Devices & Instruments industry median PB Ratio is 2.05. Nang Kuang Pharmaceutical Co's value of 1.27 is 38% below this industry median. Based on the distribution chart, Nang Kuang Pharmaceutical Co ranks #234 out of 788 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nang Kuang Pharmaceutical Co has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nang Kuang Pharmaceutical Co's PB Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nang Kuang Pharmaceutical Co ranks #234 out of 788 companies for PB Ratio. This puts Nang Kuang Pharmaceutical Co in the upper half of its industry. The industry median PB Ratio is 2.05. Nang Kuang Pharmaceutical Co's value of 1.27 is 38% below this benchmark. Historically, Nang Kuang Pharmaceutical Co's own PB Ratio has ranged from 1.28 to 3.25 over the past decade. While the company's 10-year median is 1.77 vs. the industry median of 2.05, Nang Kuang Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.05, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nang Kuang Pharmaceutical Co's current PB Ratio of 1.27 is 38% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Nang Kuang Pharmaceutical Co and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nang Kuang Pharmaceutical Co's current PB Ratio is 1.27, which is 28% below median its own 10-year median of 1.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nang Kuang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Nang Kuang Pharmaceutical Co (TPE:1752) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$46.62, compared to a current price of NT$31.35 — trading 32.8% below its estimated fair value. The current PB Ratio is 1.27, which is 28% below median its 10-year median of 1.77 and 38% below the Medical Devices & Instruments industry median of 2.05. Nang Kuang Pharmaceutical Co's overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Nang Kuang Pharmaceutical Co (TPE:1752), the current PB Ratio is 1.27 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nang Kuang Pharmaceutical Co (TPE:1752) Overvalued in 2026?
Based on GuruFocus' analysis, Nang Kuang Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$31.35 is trading 32.8% below its estimated GF Value™ of NT$46.62.
GuruFocus considers Nang Kuang Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for TPE:1752:
PB Ratio: 1.27 (28% below median its 10-year median of 1.77)
GF Value™: NT$46.62 vs. price of NT$31.35 (32.8% below fair value)
Industry Position: 38% below the Medical Devices & Instruments median (#234 of 788)
No single metric tells the full story. See the TPE:1752 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nang Kuang Pharmaceutical Co Ltd is a Taiwan-based company, its subsidiaries are engaged in the manufacture, processing, and trading, and import and export of pharmaceuticals and medical devices. Its products are Cardiovascular system medications, Gastrointestinal medications, Nervous system drugs, Nutrition and Metabolism, Hospital infusion solution, blood products, Anticancer immunomodulators, Musculoskeletal system, and Others. Geographically, the company operates in Taiwan, China, Japan, the USA, and Other countries.
88GF Score
Get the complete analysis for TPE:1752
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1752 has been successfully added to your 
